Bendamustine, thalidomide and dexamethasone is an effective salvage regimen for advanced stage multiple myeloma

British Journal of Haematology

Volumn 156, Issue 4, 2012, Pages 552-555

  Grey Davies, Elisabeth ^a   Bosworth, Jennifer L ^a   Boyd, Kevin D ^a   Ebdon, Caroline ^a   Saso, Radovan ^a   Chitnavis, Dipti ^b   Mercieca, Jane E ^c   Morgan, Gareth J ^a   Davies, Faith E ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b WEST SUFFOLK HOSPITAL   (United Kingdom)

^c EPSOM AND ST HELIER UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Bendamustine; Myeloma; Relapsed disease; Thalidomide

Indexed keywords

BENDAMUSTINE; BORTEZOMIB; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; THALIDOMIDE;

ADULT; AGED; BRADYCARDIA; CANCER STAGING; CLINICAL ARTICLE; CORTICOSTEROID INDUCED MYOPATHY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; HYPERGLYCEMIA; LETTER; LUNG EMBOLISM; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MULTIPLE MYELOMA;

EID: 84856301250     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08887.x     Document Type: Letter

References (9)

1. Bladé, J., Samson, D., Reece, D., Apperley, J., Björkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S. & Vesole, D. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. British Journal of Haematology, 102, 1115-1123.
2. Kalaycio, M. (2009) Bendamustine: a new look at an old drug. Cancer, 115, 473-479.
3. Knop, S., Straka, C., Haen, M., Schwedes, R., Hebart, H. & Einsele, H. (2005) The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica, 90, 1287-1288.
4. Leoni, L., Bailey, B., Reifert, J., Bendall, H., Zeller, R., Corbeil, J., Elliott, G. & Niemeyer, C. (2008) Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clinical Cancer Research, 309, 14.
5. Michael, M., Bruns, I., Bölke, E., Zohren, F., Czibere, A., Safaian, N., Neumann, F., Haas, R., Kobbe, G. & Fenk, R. (2010) Bendamustine in patients with relapsed or refractory multiple myeloma. European Journal of Medical Research, 15, 13-19.
6. Palumbo, A., Rajkumar, S., Dimopoulos, M.A., Richardson, P.G., San Miguel, J., Barlogie, B., Harousseau, J., Zonder, J.A., Cavo, M., Zangari, M., Attal, M., Belch, A., Knop, S., Joshua, D., Sezer, O., Ludwig, H., Vesole, D., Bladé, J., Kyle, R., Westin, J., Weber, D., Bringhen, S., Niesvizky, R., Waage, A., von Lilienfeld-Toal, M., Lonial, S., Morgan, G.J., Orlowski, R.Z., Shimizu, K., Anderson, K.C., Boccadoro, M., Durie, B.G., Sonneveld, P. & Hussein, M.A.; International Myeloma Working Group. (2008) Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia, 22, 414-423.
7. Pönisch, W., Mitrou, P.S., Merkle, K., Herold, M., Assmann, M., Wilhelm, G., Dachselt, K., Richter, P., Schirmer, V., Schulze, A., Subert, R., Harksel, B., Grobe, N., Stelzer, E., Schulze, M., Bittrich, A., Freund, M., Pasold, R., Friedrich, T., Helbig, W. & Niederwieser, D.; East German Study Group of Hematology and Oncology (OSHO). (2006) Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). Journal of Cancer Research and Clinical Oncology, 132, 205-212.
8. Pönisch, W., Rozanski, M., Goldschmidt, H., Hoffmann, F.A., Boldt, T., Schwarzer, A., Ritter, U., Rohrberg, R., Schwalbe, E., Uhlig, J., Zehrfeld, T., Schirmer, V., Haas, A., Kreibich, U. & Niederwieser, D.; East German Study Group of Haematology and Oncology (OSHO). (2008) Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial. British Journal of Haematology, 143, 191-200.
9. Ramasamy, K., Hazel, B., Mahmood, S., Corderoy, S. & Schey, S. (2011) Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease. British Journal of Haematology, Epub ahead of print, DOI:.